|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
TT-103MH is projected as alternative in new local hemostatic agent characterized some advantages like easy topical administration in all kind of bleeding diseased. Know more about the revolutionary TT-103MH antibleeding protein.
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.
We are convinced that patients will prefer topical medications for thrombosis treatment. Our company has developed a novel and innovative approach to traditional High Throughput Screening that will change the way lead compounds are identified in the areas of Hemostasis, Atherosclerosis, Aging and Thrombosis.
TT-103MH is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.
|
|
|
|
